Fig. 1: Association between the most clinically relevant DPYD defective rare variants and DPD deficiency. | The Pharmacogenomics Journal

Fig. 1: Association between the most clinically relevant DPYD defective rare variants and DPD deficiency.

From: Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity

Fig. 1: Association between the most clinically relevant DPYD defective rare variants and DPD deficiency.

Box plot showing DPD pretreatment activity assessed by the dihydrouracil/uracil ([UH2]/[U]) plasma ratio according to the patient genotype. The box represents the 25–75% quartiles, the line in the box represents the median, whiskers represent the range. The red dash line indicates the ratio threshold used to categorize patients as having partial DPD deficiency (ratio ≤10) or normal DPD activity (ratio>10). n = number of patients; ***P < 0.001; ****P < 0.0001.

Back to article page